BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open's open peer review process please email

info.bmjopen@bmj.com

BMJ Open

Study protocol for a feasibility interventional study investigating PAIN in neurorehabilitation through wearabLE SensorS (PAINLESS)

SCHOLARONE™
Manuscripts

Study protocol for a feasibility interventional study investigating PAIN in neurorehabilitation through wearabLE SensorS (PAINLESS)

Serena Moscato[1], Silvia Orlandi[1,2], Francesco Di Gregorio[3], Giada Lullini[4], Stefania Pozzi[4], Loredana Sabattini[4], Lorenzo Chiari[1,2], Fabio La Porta[4]

1. Department of Electrical, Electronic, and Information Engineering "Guglielmo Marconi" – DEI, University of Bologna, Bologna, Italy
2. Health Sciences and Technologies – Interdepartmental Center for Industrial Research (CIRI-SDV), University of Bologna, Bologna, Italy
3. UOC Medicina Riabilitativa e Neuroriabilitazione, Azienda Unità Sanitaria Locale, Bologna, Italy
4. IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia

Total length: 3991 words

Corresponding author: Fabio La Porta, fabiolaporta@mail.com

Author's email addresses: serena.moscato3@unibo.it; silvia.orlandi9@unibo.it; francesco.digregorio86@gmail.com; giada.lullini@ausl.bologna.it; stefania.pozzi@ausl.bologna.it; loredana.sabattini@isnb.it; lorenzo.chiari@unibo.it; fabiolaporta@mail.com

Keywords: pain assessment; neurorehabilitation; multiple sclerosis; wearable sensors; artificial intelligence

Abstract (max 300)

Millions of people survive injuries to the central or peripheral nervous system for which neurorehabilitation is required. Unfortunately, in addition to the physical and cognitive impairments associated with neurological deficits, many neurorehabilitation patients experience pain, often not widely recognized and inadequately treated. This is particularly true for Multiple Sclerosis (MS) patients, for whom pain is one of the most common symptoms. In clinical practice, pain assessment is usually conducted based on a subjective estimate of the patient's pain experience, mainly using self-administered questionnaires or scales. However, these tools can lead to evaluations that are not always accurate due to the influence of numerous factors, including emotional or cognitive aspects.

To date, no objective and simple-to-use clinical methods allow objective quantification of the subjective pain experience and a diagnostic differentiation between the two main types of pain (nociceptive vs. neuropathic pain). Wearable technologies are increasingly being applied in various clinical settings for monitoring patients' health parameters, allowing the real-time collection and processing of health data. As such, we aim to develop a novel automatic tool fueled by artificial intelligence (AI) to assess the presence of pain and its characteristics during neurorehabilitation treatments by evaluating the feasibility of using physiological signals collected by wearable sensors.

We aim to recruit 15 participants suffering from MS who will undergo physiotherapy treatments. During the study, participants will wear a wearable sensor (i.e., a wristband) for three consecutive days and be monitored before and after their physiotherapy sessions. Measurements of traditionally used pain assessment questionnaires and scales (i.e., painDETECT, DN4 questionnaire, EuroQol 5-dimension 3-level) and physiological signals (photoplethysmography, electrodermal activity, skin temperature, accelerometer data) will be collected. The parameters of interest from the physiological signals will be identified, and automatic classification methods will be developed using AI algorithms.

Trial registration number

NCT05747040

Strengths and limitations

- Our novel study design will allow the characterization of the physiological response to pain and its exploitation to assess the pain experience objectively.
- The use of wearable devices to measure pain will allow the recording of the physiological response when and where pain experience occurs.
- The combination of wearable devices and artificial intelligence algorithms will allow pain assessment regardless of the communication and cognitive abilities of the patient.
- This study is limited by its exploratory nature, the small sample size, and the possible influence of specific covariates, like age or type of disability.

Introduction

According to the definition of the "International Association for the Study of Pain" (IASP), pain is "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage" [1]. When pain arises from actual tissue damage, it is called nociceptive, and it has a clear protective function as it alerts the nervous system of potential threats to which it has to react adequately [4]. However, another type of pain (i.e., neuropathic pain) occurs without actual tissue damage as it is secondary to central or peripheral nervous system lesions. In this respect, neuropathic pain, which usually manifests as electric shocks, unpleasant perception of intense cold, and feelings of pressure or constriction, can occur at almost any site; it is generally chronic and, as such, can be extremely disabling [2].

Pain is one of the most common complaints of Persons with Multiple Sclerosis (PwMS) [3], an autoimmune disease characterized by inflammation, selective demyelination, and gliosis of central nervous system white matter. In particular, PwMS patients describe their pain as often widespread, chronic, and debilitating, and, as such, it may be associated with psychological distress and decreased daily functioning [4]. Since MS affects approximately 2.1 million people worldwide [5], and the prevalence of pain in this condition is between 30% and 85% [6], it can be estimated that from 630,000 to 1,800,000 PwMS around the world are likely to suffer from disabling pain. Furthermore, nociceptive and neuropathic pain may coexist in PwMS, thus posing a diagnostic and therapeutic challenge as nociceptive pain, mainly due to spasticity or other musculoskeletal impairments, may limit the effectiveness of physical therapies [2]. To make things even more complicated, the subjective experience of pain in PwMS often requires a biopsychosocial approach for assessment and treatment, where the goal is to treat the manifestations of pain at the sensory level as well as its related psychological and social aspects [7]. Hence, for appropriate and successful pain treatment in PwMS, the availability of a tool that could assess pain in its intensity and nature as objectively as possible would be highly beneficial.

In clinical practice, pain assessment is often based on subjective estimates obtained by interviewing patients, mainly using self-administered questionnaires [8]. Several self-report scales are available for the overall evaluation of pain intensity. The *Numerical Rating Scale* (NRS) is the most used, given its reported excellent reliability and validity. It consists of a 0-10 scale, where 0 is "absence of pain" and 10 is "the worst pain possible" [9]. Other scales are the *Pain Severity Subscale* of the *Multidimensional Pain Inventory* (MPI), consisting of three items on pain severity and the suffering related to pain, and the *Neuropathic Pain Scale Inventory*, which includes questions about the intensity and the quality of pain [8]. In addition, other questionnaires were specifically devised to assess symptom severity arising from neuropathic pain. Examples are the *Neuropathic Pain Symptoms Inventory* (NPSI), used for pain assessment in several populations of neurotrauma patients [8], the *painDETECT* (PD-Q), developed to measure pain's neuropathic components [10], and *Neuropathic Pain–4 questions* (Douleur Neuropathique, DN4) [11]. There are also more general questionnaires aimed at assessing the health-related quality of life in which one of the subdimension is dedicated to assessing pain, such as the EuroQoL 5-dimension 3-level (EQ-5D-3L) [12]. Finally, in addition to scales and questionnaires, pain can be assessed through "objective" instrumented methods. Some of these methods are the Quantitative Sensory Testing (QST), a battery of tests aiming at identifying pain threshold and changes in sensory function [8], the analysis of electromyographic (EMG) signals to record facial emotional expressions, voice analysis [13], functional magnetic resonance imaging (fMRI) and functional near-infrared spectroscopy (fNIRS) to monitor the main metabolic activity [13,14], or the analysis of evoked potentials recorded by the electroencephalography (EEG) [8].

Despite the availability of different tools for assessing pain, several limitations should be highlighted. First, scales and questionnaires, although undoubtedly helpful for capturing the subjective dimension of the experience of pain, can lead to inaccurate assessments due to the influence of numerous factors, not least those related to emotional or cognitive aspects. Furthermore, they can be administered reliably only to patients who are cooperative enough and not suffering from severe mental and/or communication impairments [15]. Furthermore, beyond the lack of objectivity, existing pain measurement methods may be inaccurate in discriminating between nociceptive and neuropathic pain [16]. Instrumented methods currently available could partially overcome this limitation [17,18]. Still, they can hardly be used on large populations because of the expensive costs in terms of money, time, and complex setup. Given the limitations and barriers of the existing methods, there is a need to develop new and efficient strategies for objective pain assessment. These new tools can be considered complementary to state-of-the-art pain assessment methods or new methodologies to be applied in cases where scales and questionnaires fail, such as in non-communicative patients.

Some insights potentially helpful in developing novel tools to measure pain objectively may be gleaned from the current knowledge of the neurophysiological mechanisms of pain. Indeed, pain perception involves the activation of neural mechanisms, including the Autonomic Nervous System (ANS) [19]. The ANS represents the interface between the human body's internal and external environment, acting to maintain homeostasis and respond to stress stimuli [20]. In turn, its activity influences the normal functions of several physiological mechanisms, such as skin conductance [21], heart rate, and the cardiovascular system in general [22,23]. Thus, monitoring these physiological mechanisms may provide a novel method for objective pain assessment since it would eliminate the influence of subjectivity and the impossibility of verbally communicating it. In this context, a new opportunity may be given by combining two currently widespread technologies already available in clinical and research fields: wearable sensors and artificial intelligence (AI) algorithms. The former allows us to continuously and passively record physiological signals in pervasive contexts, while the latter would enable the development of data-driven models to detect particular conditions automatically.

Several studies examined the relationship between pain and physiological signals [13,24]. Specifically, Johnson et al. [25] showed the feasibility of developing novel methods to assess pain by collecting physiological signals with wearable devices on 27 patients with sickle cell disease in a hospital setting using machine learning classifiers and regressors. In another work, Badura et al. [26] applied the same approach in a physiotherapy setting, monitoring 35 patients who rated their pain during a session of fascial therapy. In addition, our group developed an automatic dichotomous classifier for pain assessment in oncological patients

in a previous study [27]. Together with pain evaluations, real-world recordings from 31 patients were used to feed the classifier for detecting "pain" and "no pain" conditions. Best classification performances were obtained using four features extracted from photoplethysmography and electrodermal activity with the AdaBoost algorithm, reaching an accuracy equal to 72% [27]. However, despite these encouraging initial studies, the literature on the diagnostic accuracy of pain measurements involving wearable sensors is still scarce [28,29]. Furthermore, none of the previous studies explicitly focused on PwMS.

Thus, based on this preliminary evidence, the present feasibility study aims to investigate the use of physiological signals recorded by wearable sensors to achieve the following specific objectives: 1) to evaluate the feasibility of developing a differential diagnosis method to assess the absence or presence of pain; 2) to evaluate the feasibility of developing a regression model to assess pain intensity; 3) to evaluate the feasibility of developing a differential diagnosis method to discern the type of pain (nociceptive vs. neuropathic pain).

Materials and Methods

The project "PAIN in neurorehabilitation through wearabLE SensorS (PAINLESS)" is a feasibility, single cohort, interventional study.

Participants

We aim to recruit 15 participants aged between 18 and 75, undergoing neurorehabilitation motor treatments in the Neurorehabilitation Unit of IRCSS Istituto delle Scienze Neurologiche di Bologna (ISNB). Inclusion and exclusion criteria are detailed in Box 1. Before enrollment in the study, the principal investigator (PI) will check the eligibility criteria. In particular, after verifying the eligibility criteria, the PI (or a delegate) will provide the potentially eligible person with all the information and details relative to the study in simple language during an interview that will preferably take place in the presence of a caregiver. The participant is then asked to give his or her informed consent to participate in the study.

Box 1 – Inclusion and exclusion criteria

Inclusion criteria
- Age between 18 and 75 years   - Diagnosis of certainty of Multiple Sclerosis for at least three months   - Prescription of a physiotherapy-based motor rehabilitation program   - Signature of the informed consent to participate in the study
Exclusion criteria
- Heart rhythm modifying disease and/or factors such as arrhythmogenic heart disease (e.g., atrial fibrillation), presence of pacemakers and/or use of drugs capable of affecting heart rhythms, such as beta blockers (C07) or other antiarrhythmic drugs (C01)   - Cognitive impairments that preclude the possibility of providing valid informed consent, such as a disorder of consciousness or confusional state, the latter defined by temporal and/or spatial disorientation detected during ordinary conversation. In case of doubt, a simple confusional state assessment test (4AT) will be administered before enrollment   - Language comprehension skills lower than 75% in an ordinary conversation due to aphasic disorder of severe deafness despite the use of a hearing aid. In case of doubt, a simple language comprehension test (token test) will be administered before enrollment   - Linguistic expression less than 75%. In case of doubt, a simple verbal fluency test (verbal fluency by phonemic category) will be administered before enrollment   - Severe psychiatric comorbidity that may interfere with adherence to the study protocol (e.g., major depression, bipolar disease, psychosis, severe personality disorders, severe psychomotor agitation)   - History or current use of narcotic drugs (including marijuana)

> - Modification in the two weeks prior to enrollment or foreseeable modification during enrollment of any chronic pain management program, both pharmacological (cortisone for systemic use, H02; antirheumatics, M01; analgesics, N02; antiepileptics, N03; antidepressants tricyclics, N06AA; atypical antidepressants such as duloxetine or venlafaxine, N06AX) and non-pharmacological (e.g., acupuncture or other manual therapies, physical therapies, such as tecar therapy)

Intervention and outcome measures

For all enrolled participants, the intervention is represented by objective monitoring of physiological parameters, continuously recorded for 48 hours with the wearable medical device Empatica E4 [30], and concurrent subjective monitoring via specific questionnaires digitally administered via Microsoft Forms™. In particular, the intervention will be articulated across four main stages:

- t_0-t_{1a}: baseline monitoring (24h)
- t_{1a}-t_{1b}: device recharging and data downloading (1h max)
- t_{1b}-t_2: monitoring during a physiotherapy treatment session (1h)
- t_2-t_3: post- physiotherapy treatment monitoring (23 hours)

At t_0, t_{1b}, t_2, and t_3, participants will fill in subjective pain questionnaires (described in detail in the next section) to carry out a stratification and to keep monitoring it throughout the intervention in one of the following three categories: 1) absence of pain; 2) nociceptive pain; 3) neuropathic pain. A graphical depiction of the protocol is shown in Figure 1.

Reference measurements

The reference measurements, which will be taken for each participant, will be included in the following Case Report Form (CRF):

1. **a Recruitment CRF,** which will contain the demographic information, the Expanded Disability Scale [31] information about the disease and drugs;
2. **a Sleep-wake questionnaire CRF,** which the PI will administer to set reminders for each participant to fill in the monitoring questionnaire CRF.
3. **a Stratification questionnaire CRF** will allow the classification of patients into the three previously mentioned categories (absence of pain, nociceptive pain, or neuropathic pain) following the procedure described in Figure 2. In particular, this CRF will include the following tools: a) two screening questions (Pain Screen$_1$ and Pain Screen$_2$) to respectively assess the presence of current pain or in the past four weeks; b) the *painDETECT* questionnaire [10]; c) the *Doleur Neuropathique 4 Questions* (DN4) [11]; d) the *Euro Quality of Life 5-dimension 3-level* (EQ-5D-3L) [12] to evaluate the health-related quality of life.
4. **a Monitoring questionnaire CRF,** which each participant will fill in through the smartphone$_{participant}$ during the 48h-monitoring, including information about any experienced pain.
5. **a Monitoring-treatment questionnaire CRF** will be administered by the PI (or his delegate) through the smartphone$_{project}$ to each participant during the motor neurorehabilitation treatment. It is a reduced version of the Monitoring questionnaire CRF.

Wearable devices and physiological signals

Each participant will be asked to wear the Empatica E4 wristband, a wearable medical device that records the following physiological signals:

1. **Photoplethysmography (PPG)**, reporting variations in blood volume flow that occur with each heartbeat, affected by both the sympathetic and parasympathetic nervous systems. PPG signal can be exploited to estimate the heart rate, thus allowing the heart rate variability (HRV) analysis and interesting features can be extracted by conducting a more in-depth morphological analysis [32];
2. **Electrodermal Activity (EDA)**, representing the activation of the eccrine sweat glands, innervated by the sympathetic nervous system, representing an arousal index Features related to pain sensations

can be extracted either from the whole signal or from the two principal components, the tonic (slow changes) and the phasic (fast changes) components [21];

3. **Skin temperature (SKT)**, an index of sympathetic activation, mainly depending on the amount of superficial blood flow;

4. **Accelerometer data (ACC),** recording physical activity and movement.

Experimental pipeline

The intervention will consist of the seven following phases:

- t_0: The CRF Stratification questionnaire will be administered through a smartphone by the PI (or his delegate). The participant will then be asked to wear the Empatica E4 wristband and be given the smartphone$_{participant}$, which will be used to fulfill the Monitoring questionnaire CRF. Reminders will be set to fill in the questionnaire based on the Sleep-Wake questionnaire CRF administered in this phase.

- t_0-t_{1a}: The participant will wear the Empatica E4 wristband and complete the Monitoring questionnaire CRF. Reminders will be set hourly during waking hours.

- t_{1a}-t_{1b}: The participant will return to the clinic 24 hours after t_0 and drop off the Empatica E4 and the smartphone$_{participant}$ for data downloading and device recharging. After about an hour, the participant will be asked again to wear the Empatica E4. Then, the Stratification questionnaire CRF will be administered, and the motor neurorehabilitation treatment will commence.

- t_{1b}-t_2: The participant will undergo the motor neurorehabilitation treatment, and every 10 minutes, the PI (or his delegate) will administer the Monitoring-treatment questionnaire CRF through the smartphone$_{project}$.

- t_2: The Stratification questionnaire CRF will be administered, and the participant will receive back the smartphone$_{participant}$.

- t_2-t_3: The participant will wear the Empatica E4 wristband and complete the Monitoring questionnaire CRF. Reminders will be set again hourly during waking hours.

- t_3: Finally, the participant will return to the clinic 24 hours after t_2 and drop off the Empatica E4 and the smartphone$_{participant}$.

Signal and data analysis

Physiological signals recorded through the Empatica E4 wristband will be analyzed in four successive phases: 1) Preprocessing (artifact mitigation, filtering); 2) Segmentation (time-windows detection of physiological signals linked to the assessments); 3) Signal processing and feature extraction; 4) Feature selection. Following this pipeline, we will implement AI algorithms to develop the classifiers and regressors methods indicated in Box 2. Classifiers and regressors will be trained and tested based on the outcomes from the Stratification questionnaire CRF, Monitoring questionnaire CRF, and Monitoring-treatment questionnaire CRF. Validation will be conducted by testing the Leave-One-Subject-Out cross-validation and 10-fold cross-validation. We will also consider adding covariates, either from the Monitoring questionnaire CRF or personal data (e.g., age, information about the pathology, and use of drugs). This will allow verifying, both on a quantitative and qualitative basis, whether there are differences in physiological parameters related to these specific covariates.

The performance of the classifiers will be assessed using the following indicators: accuracy, sensitivity, specificity, and area under the Receiving Operating Characteristic (ROC) curve (or precision and recall when a multi-class classification is applied). Instead, the regression models' performance will be assessed using the following indicators: root mean squared error, absolute error, relative error, and correlation.

Box 2 – Classifiers and regressors methods for pain assessment

Pain class	Absence vs Presence of pain
	Nociceptive vs Neuropathic pain
	Absence of pain vs Nociceptive pain vs Neuropathic pain
Pain intensity	Multi-class classifier, based on literature guidelines
	Regression model

Objectives and related endpoints

1. **Feasibility of developing a differential diagnosis method based on physiological signals recorded using wearable sensors to assess the absence or presence of pain.** The related primary endpoint will be evaluated based on the number of available instances to be processed for determining the absence/presence of pain, which means the number of concurrent physiological signals registrations and pain assessments. If this endpoint is met, a predictive test will be developed based on AI techniques and physiological parameters. The diagnostic performance of this test will be evaluated against the gold standard (questionnaires) by evaluating standard performance indicators (i.e., sensitivity, specificity, predictive values). The endpoint will be considered achieved if at least 80% of the instances are available. The diagnostic accuracy will be calculated using the CRF Stratification and CRF Monitoring questionnaires as a reference. The threshold for the diagnostic accuracy to define the endpoint achieved is set at 75%.

2. **Feasibility of developing a regression model based on physiological signals recorded using wearable sensors to assess pain intensity (secondary endpoint).** The related secondary endpoint will be evaluated based on the number of available instances to be processed to assess pain intensity, i.e., the number of concurrent physiological signals registrations and pain assessments. If this endpoint is met, a regression model will be developed based on AI techniques and physiological parameters. The diagnostic performance of this test will be evaluated against the gold standard (questionnaires) by evaluating standard performance indicators (i.e., accuracy, mean squared error). The endpoint will be achieved if at least 80% of the instances are available. The coefficient of determination of the regression model will be calculated using the CRF Stratification questionnaire and CRF Monitoring questionnaire as a reference. The threshold for the coefficient of determination to define the endpoint achieved is set at 0.5.

3. **Feasibility of developing a differential diagnosis method based on physiological signals recorded using wearable sensors to discern between nociceptive and neuropathic pain (secondary endpoint).** The related secondary endpoint will be assessed based on the number of available instances to be processed to distinguish between nociceptive and neuropathic pain, i.e., the number of concurrent physiological signals registrations and pain assessments. If this endpoint is met, a predictive test will be developed based on AI techniques and physiological parameters. The diagnostic performance of this test will be evaluated against the gold standard (questionnaires) by evaluating standard performance indicators (i.e., sensitivity, specificity, predictive values). The endpoint will be considered achieved if at least 80% of the instances are available. The diagnostic accuracy will be calculated using the CRF Stratification and CRF Monitoring questionnaires as a reference. The threshold to define the endpoint achieved is set at 75%.

Sample size

Given the study's exploratory nature, the effect size is unknown; thus, it is not possible to calculate the sample size accurately.

Ethics and Dissemination

The study will be conducted according to the ethical principles established in the Declaration of Helsinki and has been subjected to approval by the local Ethical Committee (285-2022-SPER-AUSLBO). Any changes to the protocol will be proposed to the local Ethical Committee as a request for amendment. Although it is not

foreseen that there will be a direct short-term benefit to participants, the research protocol presents minimal risks for the participants and no burden, as required by Article 28 of the Declaration of Helsinki.

Personal data will be retained in agreement with the GDPR guidance for ten years. Specifically, the PI and co-PIs will be responsible for archiving and preserving the essential study documents before, during, and after the completion of the study, according to the timeframe required by the current regulations and good clinical practice.

Researchers involved in the study will disseminate the results in a timely and complete manner, participating in conferences and writing scientific articles for submission to international journals. In addition, the findings from the study will form part of a doctoral dissertation for one of the authors (SM). The researchers will scrupulously, objectively, and impartially provide as much evidence and information as possible on aspects such as the state-of-the-art literature before the study, the original purpose, and methods defined before conducting the research, any changes in objectives and methods since the study were commenced, the significant results achieved, including negative or null results and, finally, the possible interpretations, applicability, and limitations of the findings.

Discussion

In regular clinical practice, pain assessment is usually carried out by administering subjective scales and questionnaires. Although their usefulness for the subjective quantification of pain, these tools can lead to inaccurate assessments due to the influence of many factors, such as emotional and cognitive factors. In addition, they cannot be administered to those patients unable to communicate verbally. Therefore, identifying optimal physiological parameters recorded through wearable devices and using artificial intelligence algorithms would allow the development of automatic methods capable of determining the absence or presence of pain in MS patients, its intensity, and distinguishing pain as nociceptive or neuropathic.

Such continuous and objective pain monitoring in everyday life activities and during treatments would overcome the limitations imposed by the tools currently used in clinical practice. In particular, continuous and objective monitoring would bring about several advantages. First, this pain assessment disregards the patients' ability or willingness to communicate their pain verbally. Second, this approach is supposed to provide a completely automatic method that would not require spending time ad hoc to administer scales and questionnaires, as it could be used in hospital or daily life contexts while patients are involved in other activities. Lastly, having a more reliable method to discriminate between nociceptive and neuropathic pain would allow a better personalization of the antalgic therapy.

The long-term goal is to integrate such an innovative method into regular clinical practice as a tool for clinical decision-making for the antalgic therapy to be chosen. Implementing this method would allow PwMS to be monitored both during neurorehabilitation treatment and in a pervasive context. This would allow for a timelier assessment of the patient's pain, ultimately aiming to ameliorate their quality of life. Prospectively, if properly calibrated, such a method could allow quantification and monitoring of pain in patients unable to express it verbally, such as patients with severe brain injury, in a minimally conscious state, or with aphasia.

An innovative aspect of this study relies on the possibility of overcoming the "etiological" boundaries of pain at the measurement level. This would be extremely useful, considering that, in many pathologies, different types of pain may coexist. For example, in brain injury, there may be a mix of nociceptive and neuropathic pain, both of central and peripheral origin. This study could bring initial insights into how pain can be measured by recording a minimum set of physiological parameters based on physiological indicators invariant to the pathology. In other words, we will be able to assess whether the parameters to be measured are independent of the underlying pathology, precisely as is the case for different physiological parameters such as body temperature or heart rate. For the latter, differences of quantitative nature (e.g., fever) give rise to specific diagnostic profiles only in combination with other data (e.g., body temperature changes and other diagnostic indicators), being the measurement of the temperature parameter independent of the pathology that modifies

it. Similarly, from the combination of physiological parameters of pain, diagnostic combinations ("profiles") could be identified for specific pathologies.

The proposed study is also relevant for health systems because it aims to improve the pain assessment phase, which is necessary to choose the most appropriate antalgic therapy for the patient. In addition, such a system would allow the prescription of more personalized pain treatment plans, make efficient use of resources, and minimize the waste resulting from the incorrect choice of ineffective strategies to improve the patient's pain status. In addition, the proposed protocol is also relevant in terms of research, as the availability of an objective system of pain quantification, together with the already available subjective assessment tools, would make the quantification of treatment effects in the context of RCTs and other studies undoubtedly more accurate and less prone to interpretive bias.

The methodology presented here may suffer from several limitations. First, being designed as an exploratory feasibility study, the limited sample size may hinder the development of robust and reliable methods for objectively assessing pain and, consequently, achieving reliable results and good performance. Furthermore, additional specific personal, contextual, or health-related factors (e.g., age, sex, physical activity level, type of disability) can significantly impact the physiological parameters used to develop automatic pain assessment methods. Thus, our models may not be robust enough to properly assess pain should these factors not be adequately controlled.

Conclusion

In this paper, we presented a protocol to evaluate the feasibility of developing automatic methods for pain assessment in Persons with Multiple Sclerosis based on physiological signals and AI algorithms. In addition, we illustrated the intervention by highlighting the state-of-the-art and innovative tools to obtain reliable and robust methods for automatic pain assessment. Such an approach, if proven feasible, can lead to significant progress in the field of pain management by providing a better characterization of pain and, therefore, more timely and efficient interventions to control it.

Contributions

SM: Conceptualization, Methodology, Data processing, Formal analysis, Manuscript – initial draft preparation, review, and editing. SO: Conceptualization, Methodology, Data processing, Formal analysis, Manuscript – initial draft preparation, review, and editing. FDG: Methodology, Manuscript – review and editing. GL: Conceptualization, Manuscript – review and editing. SP: Site facilitator, Manuscript – review and editing. LS: Site facilitator, Methodology, Manuscript – review and editing. LC: Conceptualization, Methodology, Funding acquisition, Manuscript – review, and editing. FLP: Conceptualization, Methodology, Formal analysis, Manuscript – initial draft preparation, review, and editing.

Fundings

Competing Interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Bibliography

1   Raja SN, Carr DB, Cohen M, *et al.* The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain* 2020;**161**:1976–82. doi:10.1097/j.pain.0000000000001939

2   Clarke C, Howard R, Rossor M, *et al. Neurology: A Queen Square textbook: Second edition*. 2016. doi:10.1002/9781118486160

3   Seixas D, Foley P, Palace J, *et al.* Pain in multiple sclerosis: A systematic review of neuroimaging studies. *NeuroImage Clin* 2014;**5**:322–31. doi:10.1016/j.nicl.2014.06.014

4   Sullivan AB, Scheman J, LoPresti A, *et al.* Interdisciplinary Treatment of Patients with Multiple Sclerosis and Chronic Pain. *Int J MS Care* 2012;**14**:216–20. doi:10.7224/1537-2073-14.4.216

5   O'Sullivan SB, Schmitz TJ, Fulk GD. *Physical Rehabilitation*. 2014.

6   Marck CH, De Livera AM, Weiland TJ, *et al.* Pain in People with Multiple Sclerosis: Associations with Modifiable Lifestyle Factors, Fatigue, Depression, Anxiety, and Mental Health Quality of Life. *Front Neurol* 2017;**8**. doi:10.3389/fneur.2017.00461

7   Benrud-Larson LM, Wegener ST. Chronic pain in neurorehabilitation populations: Prevalence, severity and impact. *NeuroRehabilitation* 2000;**14**:127–37. doi:10.3233/NRE-2000-14302

8   Widerstrom-Noga E. The assessment and treatment of pain syndromes in neurorehabilitation. In: *Oxford Textbook of Neurorehabilitation*. 2015. 314–27.

9   Haefeli M, Elfering A. Pain assessment. *Eur Spine J* 2006;**15**:S17–24. doi:10.1007/s00586-005-1044-x

10   Freynhagen R, Baron R, Gockel U, *et al.* pain DETECT : a new screening questionnaire to identify neuropathic components in patients with back pain. *Curr Med Res Opin* 2006;**22**:1911–20. doi:10.1185/030079906X132488

11   Pfizer. Pharmacy focus on pain - DN4 Questionnaire. 2016. https://www.pfizerpro.ie/sites/default/files/dn.pdf

12   Mozzi A, Meregaglia M, Lazzaro C, *et al.* A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. *Clin Outcomes Res* 2016;:267. doi:10.2147/CEOR.S98226

13   Werner P, Lopez-Martinez D, Walter S, *et al.* Automatic Recognition Methods Supporting Pain Assessment: A Survey. *IEEE Trans Affect Comput* 2019;**X**:1–1. doi:10.1109/TAFFC.2019.2946774

14   Morton DL, Jones AKP. Brain imaging of pain : state of the art. 2016;:613–24.

15   Subramaniam SD, Doss B, Chanderasekar LD, *et al.* Scope of physiological and behavioural pain assessment techniques in children – A review. *Healthc Technol Lett* 2018;**5**:124–9. doi:10.1049/htl.2017.0108

16   Gilron I, Baron R, Jensen T. Neuropathic Pain: Principles of Diagnosis and Treatment. *MAYO Clin Proc* 2015;**90**:532–45. doi:10.1016/j.mayocp.2015.01.018

17   Dou Z, Yang L. The Application of Functional Magnetic Resonance Imaging in Neuropathic Pain. In: *Medical Imaging - Principles and Applications [Working Title]*. IntechOpen 2019. doi:10.5772/intechopen.89200

18   Teixeira M, Mancini C, Wicht CA, *et al.* Beta Electroencephalographic Oscillation Is a Potential GABAergic Biomarker of Chronic Peripheral Neuropathic Pain. *Front Neurosci* 2021;**15**. doi:10.3389/fnins.2021.594536

19   Hohenschurz-Schmidt DJ, Calcagnini G, Dipasquale O, *et al.* Linking Pain Sensation to the

Autonomic Nervous System: The Role of the Anterior Cingulate and Periaqueductal Gray Resting-State Networks. *Front Neurosci* 2020;**14**. doi:10.3389/fnins.2020.00147

20   Cortelli P, Giannini G, Favoni V, *et al.* Nociception and autonomic nervous system. *Neurol Sci* 2013;**34**. doi:10.1007/s10072-013-1391-z

21   Boucsein W. *Electrodermal Activity*. Boston, MA: : Springer US 2012. doi:10.1007/978-1-4614-1126-0

22   Hui TKL, Sherratt RS. Coverage of Emotion Recognition for Common Wearable Biosensors. *Biosensors* 2018;**8**:30. doi:10.3390/bios8020030

23   Li F, Yang L, Shi H, *et al.* Differences in photoplethysmography morphological features and feature time series between two opposite emotions: Happiness and sadness. *Artery Res* 2017;**18**:7. doi:10.1016/j.artres.2017.02.003

24   Naranjo-Hernandez D, Reina-Tosina J, Roa LM. Sensor Technologies to Manage the Physiological Traits of Chronic Pain: A Review. *Sensors (Basel)* 2020;**20**. doi:10.3390/s20020365

25   Johnson A, Yang F, Gollarahalli S, *et al.* Use of Mobile Health Apps and Wearable Technology to Assess Changes and Predict Pain During Treatment of Acute Pain in Sickle Cell Disease: Feasibility Study. *JMIR mHealth uHealth* 2019;**7**:e13671. doi:10.2196/13671

26   Badura A, Masłowska A, Myśliwiec A, *et al.* Multimodal Signal Analysis for Pain Recognition in Physiotherapy Using Wavelet Scattering Transform. *Sensors* 2021;**21**:1311. doi:10.3390/s21041311

27   Moscato S, Orlandi S, Giannelli A, *et al.* Automatic pain assessment on cancer patients using physiological signals recorded in real-world contexts. In: *44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)*. IEEE 2022. 1931–4. doi:10.1109/EMBC48229.2022.9871990

28   Leroux A, Rzasa-Lynn R, Crainiceanu C, *et al.* Wearable Devices: Current Status and Opportunities in Pain Assessment and Management. *Digit Biomarkers* 2021;**5**:89–102. doi:10.1159/000515576

29   Chen J, Abbod M, Shieh J-S. Pain and Stress Detection Using Wearable Sensors and Devices—A Review. *Sensors* 2021;**21**:1030. doi:10.3390/s21041030

30   EMPATICA I. Empatica Sensors Empatica E4 TechSpecs. 2015;:4–8.www.empatica.com/docs (accessed 31 Jan 2019).

31   Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). *Neurology* 1983;**33**:1444–1444. doi:10.1212/WNL.33.11.1444

32   Elgendi M. On the Analysis of Fingertip Photoplethysmogram Signals. *Curr Cardiol Rev* 2012;**8**:14–25. doi:10.2174/157340312801215782

1

Study flowchart

168x98mm (220 x 220 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

START

PainScreen$_2$
PainScreen$_2$
painDETECT$_{mod}$
DN4

Total score
painDETECT$_{mod}$

Total score
DN4

Summary
score$_{painDETECTmod}$

Summary score$_{DN4}$

0	1	2	3
Absence of pain	Nociceptive pain	Unclear	Neuropathic pain

0	1	2
Absence of pain	Nociceptive pain	Neuropathic pain

Summary score$_{painDETECTmod}$ +
Summary score$_{DN4}$ =
Summary Score$_{Pain}$

0	1-2	3-5
Absence of pain	Possible Nociceptive pain	Possible Neuropathic pain

Stratification algorithm

164x144mm (150 x 150 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

Reporting Item			Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1

Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	n/a
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	8
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	n/a
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	8
Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and	n/a

other individuals or groups overseeing the trial, if

applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	2-4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	2-3
Objectives	#7	Specific objectives or hypotheses	4
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4

Methods: Participants, interventions, and outcomes

Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Box 1
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	4-5
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	n/a
Interventions: adherance	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	n/a
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6

Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	n/a
Methods: Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque,	n/a

sealed envelopes), describing any steps to conceal the

sequence until interventions are assigned

Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a

Methods: Data collection, management, and analysis

Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	5

Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a
Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	n/a
Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	5-6
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	n/a
Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	n/a

Methods: Monitoring

| Data monitoring: formal committee | #21a | Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further | n/a |

1
2
3
4
5
6
7

details about its charter can be found, if not in the

protocol. Alternatively, an explanation of why a DMC is

not needed

Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a
Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a

Ethics and dissemination

Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	7
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	7

Consent or assent	[#26a](#)	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
Consent or assent: ancillary studies	[#26b](#)	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	7
Confidentiality	[#27](#)	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	7
Declaration of interests	[#28](#)	Financial and other competing interests for principal investigators for the overall trial and each study site	n/a
Data access	[#29](#)	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a
Ancillary and post trial care	[#30](#)	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	[#31a](#)	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	7

| Dissemination policy: authorship | #31b | Authorship eligibility guidelines and any intended use of professional writers | n/a |
| Dissemination policy: reproducible research | #31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code | n/a |

Appendices

| Informed consent materials | #32 | Model consent form and other related documentation given to participants and authorised surrogates | n/a |
| Biological specimens | #33 | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable | n/a |

The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 06. March 2023 using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with Penelope.ai

BMJ Open

Study protocol for a feasibility interventional study investigating PAIN in neurorehabilitation through wearabLE SensorS (PAINLESS)

Journal:	*BMJ Open*
Manuscript ID	bmjopen-2023-073534.R1
Article Type:	Protocol
Date Submitted by the Author:	20-Jul-2023
Complete List of Authors:	Moscato, Serena; Alma Mater Studiorum University of Bologna, Department of Electrical, Electronic, and Information Engineering "Guglielmo Marconi" – DEI Orlandi, Silvia; Alma Mater Studiorum University of Bologna, Department of Electrical, Electronic, and Information Engineering "Guglielmo Marconi" - DEI; Alma Mater Studiorum University of Bologna, Health Science and Technologies - Interdepartmental Center for Industrial Research (CIRI-SDV) Di Gregorio, Francesco; Azienda Unità Sanitaria Locale di Bologna, UOC Medicina Riabilitativa e Neuroriabilitazione Lullini, Giada; IRCCS Istituto Delle Scienze Neurologiche di Bologna Pozzi, Stefania; Azienda Unità Sanitaria Locale di Bologna, DATER Riabilitazione Ospedaliera, UA Riabilitazione Sabattini, Loredana; IRCCS Istituto Delle Scienze Neurologiche di Bologna Chiari, Lorenzo; Alma Mater Studiorum University of Bologna, Department of Electrical, Electronic and Information Engineering «Guglielmo Marconi» - DEI; Alma Mater Studiorum University of Bologna, Health Sciences and Technologies - Interdepartmental Center for Industrial Research (CIRI-SDV) La Porta, Fabio; IRCCS Istituto Delle Scienze Neurologiche di Bologna
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Research methods
Keywords:	PAIN MANAGEMENT, Neurological pain < NEUROLOGY, Multiple sclerosis < NEUROLOGY, REHABILITATION MEDICINE

SCHOLARONE™
Manuscripts

Study protocol for a feasibility interventional study investigating PAIN in neurorehabilitation through wearabLE SensorS (PAINLESS)

Serena Moscato[1], Silvia Orlandi[1,2], Francesco Di Gregorio[3], Giada Lullini[4], Stefania Pozzi[4], Loredana Sabattini[5], Lorenzo Chiari[1,2], Fabio La Porta[4]

1. Department of Electrical, Electronic, and Information Engineering "Guglielmo Marconi" – DEI, University of Bologna, Bologna, Italy
2. Health Sciences and Technologies – Interdepartmental Center for Industrial Research (CIRI-SDV), University of Bologna, Bologna, Italy
3. UOC Medicina Riabilitativa e Neuroriabilitazione, Azienda Unità Sanitaria Locale, Bologna, Italy
4. Azienda AUSL Bologna, DATER Riabilitazione Ospedaliera, UA Riabilitazione Ospedale Bellaria, Bologna, italy
5. IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italia

Word count: 3991

Correspondence to:

Fabio La Porta

fabiolaporta@mail.com

Author's email addresses: serena.moscato3@unibo.it; silvia.orlandi9@unibo.it; francesco.digregorio86@gmail.com; giada.lullini@ausl.bologna.it; stefania.pozzi@ausl.bologna.it; loredana.sabattini@isnb.it; lorenzo.chiari@unibo.it; fabiolaporta@mail.com

Abstract

Introduction: Millions of people survive injuries to the central or peripheral nervous system for which neurorehabilitation is required. In addition to the physical and cognitive impairments, many neurorehabilitation patients experience pain, often not widely recognized and inadequately treated. This is particularly true for Multiple Sclerosis (MS) patients, for whom pain is one of the most common symptoms. In clinical practice,

pain assessment is usually conducted based on a subjective estimate. This approach can lead to inaccurate evaluations due to the influence of numerous factors, including emotional or cognitive aspects. To date, no objective and simple to use clinical methods allow objective quantification of pain and the diagnostic differentiation between the two main types of pain (nociceptive vs. neuropathic). Wearable technologies and artificial intelligence (AI) have the potential to bridge this gap by continuously monitoring patients' health parameters and extracting meaningful information from them. Therefore, we propose to develop a new automatic AI-powered tool to assess pain and its characteristics during neurorehabilitation treatments using physiological signals collected by wearable sensors.

Methods and analysis: We aim to recruit 15 participants suffering from MS undergoing physiotherapy treatment. During the study, participants will wear a wristband for three consecutive days and be monitored before and after their physiotherapy sessions. Measurement of traditionally used pain assessment questionnaires and scales (i.e., painDETECT, DN4 questionnaire, EuroQoL-5-dimension-3-level) and physiological signals (photoplethysmography, electrodermal activity, skin temperature, accelerometer data) will be collected. Relevant parameters from physiological signals will be identified, and AI algorithms will be used to develop automatic classification methods.

Ethics and dissemination: The study has been approved by the local Ethical Committee (285-2022-SPER-AUSLBO). Participant are required to provide written informed consent. The results will be disseminated through contributions to international conferences and scientific journals, and they will also be included in a doctoral dissertation.

Study registration: ClinicalTrials.gov, NCT05747040.

Strengths and limitations of this study

- Our novel study design will allow the characterization of the physiological response to pain and its exploitation to assess the pain experience objectively.
- The use of wearable devices to measure pain will allow the recording of the physiological response when and where pain experience occurs.
- The combination of wearable devices and artificial intelligence algorithms will allow pain assessment regardless of the communication and cognitive abilities of the patient.
- This study is limited by its exploratory nature, the small sample size, and the possible influence of specific covariates, like age or type of disability.

Introduction

According to the definition of the "International Association for the Study of Pain" (IASP), pain is "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage" [1]. When pain arises from actual tissue damage, it is called nociceptive, and it has a clear protective function as it alerts the nervous system of potential threats to which it has to react adequately [4]. However, another type of pain (i.e., neuropathic pain) occurs without actual tissue damage as it is secondary to central or peripheral nervous system lesions. In this respect, neuropathic pain, which usually manifests as electric shocks, unpleasant perception of intense cold, and feelings of pressure or constriction, can occur at almost any site; it is generally chronic and, as such, can be extremely disabling [2].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Pain is one of the most common complaints of Persons with Multiple Sclerosis (PwMS) [3], an autoimmune disease characterized by inflammation, selective demyelination, and gliosis of central nervous system white matter. In particular, PwMS patients describe their pain as often widespread, chronic, and debilitating, and, as such, it may be associated with psychological distress and decreased daily functioning [4]. Since MS affects approximately 2.1 million people worldwide [5], and the prevalence of pain in this condition is between 30% and 85% [6], it can be estimated that from 630,000 to 1,800,000 PwMS around the world are likely to suffer from disabling pain. Furthermore, nociceptive and neuropathic pain may coexist in PwMS, thus posing a diagnostic and therapeutic challenge as nociceptive pain, mainly due to spasticity or other musculoskeletal impairments, may limit the effectiveness of physical therapies [2]. To make things even more complicated, the subjective experience of pain in PwMS often requires a biopsychosocial approach for assessment and treatment, where the goal is to treat the manifestations of pain at the sensory level as well as its related psychological and social aspects [7]. Hence, for appropriate and successful pain treatment in PwMS, the availability of a tool that could assess pain in its intensity and nature as objectively as possible would be highly beneficial.

In clinical practice, pain assessment is often based on subjective estimates obtained by interviewing patients, mainly using self-administered questionnaires [8]. Several self-report scales are available for the overall evaluation of pain intensity. The *Numerical Rating Scale* (NRS) is the most used, given its reported excellent reliability and validity. It consists of a 0-10 scale, where 0 is "absence of pain" and 10 is "the worst pain possible" [9]. Other scales are the *Pain Severity Subscale* of the *Multidimensional Pain Inventory* (MPI), consisting of three items on pain severity and the suffering related to pain, and the *Neuropathic Pain Scale Inventory*, which includes questions about the intensity and the quality of pain [8]. In addition, other questionnaires were specifically devised to assess symptom severity arising from neuropathic pain. Examples are the *Neuropathic Pain Symptoms Inventory* (NPSI), used for pain assessment in several populations of neurotrauma patients [8], the *painDETECT* (PD-Q), developed to measure pain's neuropathic components [10], and *Neuropathic Pain–4 questions* (Douleur Neuropathique, DN4) [11]. There are also more general questionnaires aimed at assessing the health-related quality of life in which one of the subdimension is dedicated to assessing pain, such as the EuroQoL 5-dimension 3-level (EQ-5D-3L) [12]. Finally, in addition to scales and questionnaires, pain can be assessed through "objective" instrumented methods. Some of these methods are the Quantitative Sensory Testing (QST), a battery of tests aiming at identifying pain threshold and changes in sensory function [8], the analysis of electromyographic (EMG) signals to record facial emotional expressions, voice analysis [13], functional magnetic resonance imaging (fMRI) and functional near-infrared spectroscopy (fNIRS) to monitor the main metabolic activity [13,14], or the analysis of evoked potentials recorded by the electroencephalography (EEG) [8].

Despite the availability of different tools for assessing pain, several limitations should be highlighted. First, scales and questionnaires, although undoubtedly helpful for capturing the subjective dimension of the experience of pain, can lead to inaccurate assessments due to the influence of numerous factors, not least those related to emotional or cognitive aspects. Furthermore, they can be administered reliably only to patients who are cooperative enough and not suffering from severe mental and/or communication impairments [15]. Furthermore, beyond the lack of objectivity, existing pain measurement methods may be inaccurate in discriminating between nociceptive and neuropathic pain [16]. Instrumented methods currently available could partially overcome this limitation [17,18]. Still, they can hardly be used on large populations because of the expensive costs in terms of money, time, and complex setup. Given the limitations and barriers of the existing methods, there is a need to develop new and efficient strategies for objective pain assessment. These new tools can be considered complementary to state-of-the-art pain assessment methods or new methodologies to be applied in cases where scales and questionnaires fail, such as in non-communicative patients.

Some insights potentially helpful in developing novel tools to measure pain objectively may be gleaned from the current knowledge of the neurophysiological mechanisms of pain. Indeed, pain perception involves the activation of neural mechanisms, including the Autonomic Nervous System (ANS) [19]. The ANS represents the interface between the human body's internal and external environment, acting to maintain homeostasis and

respond to stress stimuli [20]. In turn, its activity influences the normal functions of several physiological mechanisms, such as skin conductance [21], heart rate, and the cardiovascular system in general [22,23]. Thus, monitoring these physiological mechanisms may provide a novel method for objective pain assessment since it would eliminate the influence of subjectivity and the impossibility of verbally communicating it. In this context, a new opportunity may be given by combining two currently widespread technologies already available in clinical and research fields: wearable sensors and artificial intelligence (AI) algorithms. The former allows us to continuously and passively record physiological signals in pervasive contexts, while the latter would enable the development of data-driven models to detect particular conditions automatically.

Several studies examined the relationship between pain and physiological signals [13,24]. Specifically, Johnson et al. [25] showed the feasibility of developing novel methods to assess pain by collecting physiological signals with wearable devices on 27 patients with sickle cell disease in a hospital setting using machine learning classifiers and regressors. In another work, Badura et al. [26] applied the same approach in a physiotherapy setting, monitoring 35 patients who rated their pain during a session of fascial therapy. In addition, our group developed an automatic dichotomous classifier for pain assessment in oncological patients in a previous study [27]. Together with pain evaluations, real-world recordings from 31 patients were used to feed the classifier for detecting "pain" and "no pain" conditions. Best classification performances were obtained using four features extracted from photoplethysmography and electrodermal activity with the AdaBoost algorithm, reaching an accuracy equal to 72% [27]. However, despite these encouraging initial studies, the literature on the diagnostic accuracy of pain measurements involving wearable sensors is still scarce [28,29]. Furthermore, none of the previous studies explicitly focused on PwMS.

Thus, based on this preliminary evidence, the present feasibility study aims to investigate the use of physiological signals recorded by wearable sensors to achieve the following specific objectives: 1) to evaluate the feasibility of developing a differential diagnosis method to assess the absence or presence of pain; 2) to evaluate the feasibility of developing a regression model to assess pain intensity; 3) to evaluate the feasibility of developing a differential diagnosis method to discern the type of pain (nociceptive vs. neuropathic pain).

Methods and analysis

Study design and participants

The 'PAIN in neurorehabilitation through wearabLE SensorS (PAINLESS)' project is a feasibility, single cohort, interventional study.

We aim to recruit 15 participants aged between 18 and 75, undergoing neurorehabilitation motor treatments in the Neurorehabilitation Unit of IRCSS Istituto delle Scienze Neurologiche di Bologna (ISNB). Inclusion and exclusion criteria are detailed in Box 1. Before enrollment in the study, the principal investigator (PI) will check the eligibility criteria. In particular, after verifying the eligibility criteria, the PI (or a delegate) will provide the potentially eligible person with all the information and details relative to the study in simple language during an interview that will preferably take place in the presence of a caregiver. After having assessed the patientsì understanding of the nature of the procedure, the risks and benefits, reasonable alternatives and their risks and benefits, the participant is asked to give his or her written informed consent to participate in the study (see Supplemental Material).

Box 1. Inclusion and exclusion criteria

Inclusion criteria
• Age between 18 and 75 years
• Diagnosis of certainty of Multiple Sclerosis for at least three months

- Prescription of a physiotherapy-based motor rehabilitation program
- Signature of the informed consent to participate in the study

Exclusion criteria

- Heart rhythm modifying disease and/or factors such as arrhythmogenic heart disease (e.g., atrial fibrillation), presence of pacemakers and/or use of drugs capable of affecting heart rhythms, such as beta blockers (C07) or other antiarrhythmic drugs (C01)
- Cognitive impairments that preclude the possibility of providing valid informed consent, such as a disorder of consciousness or confusional state, the latter defined by temporal and/or spatial disorientation detected during ordinary conversation. In case of doubt, a simple confusional state assessment test (4AT) will be administered before enrollment
- Language comprehension skills lower than 75% in an ordinary conversation due to aphasic disorder of severe deafness despite the use of a hearing aid. In case of doubt, a simple language comprehension test (token test) will be administered before enrollment
- Linguistic expression less than 75%. In case of doubt, a simple verbal fluency test (verbal fluency by phonemic category) will be administered before enrollment
- Severe psychiatric comorbidity that may interfere with adherence to the study protocol (e.g., major depression, bipolar disease, psychosis, severe personality disorders, severe psychomotor agitation)
- History or current use of narcotic drugs (including marijuana)
- Modification in the two weeks prior to enrollment or foreseeable modification during enrollment of any chronic pain management program, both pharmacological (cortisone for systemic use, H02; antirheumatics, M01; analgesics, N02; antiepileptics, N03; antidepressants tricyclics, N06AA; atypical antidepressants such as duloxetine or venlafaxine, N06AX) and non-pharmacological (e.g., acupuncture or other manual therapies, physical therapies, such as tecar therapy)

Intervention and outcome measures

For all enrolled participants, the intervention is represented by objective monitoring of physiological parameters, continuously recorded for 48 hours with the wearable medical device Empatica E4 [30], and concurrent subjective monitoring via specific questionnaires digitally administered via Microsoft Forms™. In particular, the intervention will be articulated across four main stages:

- t_0-t_{1a}: baseline monitoring (24h)
- t_{1a}-t_{1b}: device recharging and data downloading (1h max)
- t_{1b}-t_2: monitoring during a physiotherapy treatment session (1h)
- t_2-t_3: post- physiotherapy treatment monitoring (23 hours)

At t_0, t_{1b}, t_2, and t_3, participants will fill in subjective pain questionnaires (described in detail in the next section) to carry out a stratification and to keep monitoring it throughout the intervention in one of the following three categories: 1) absence of pain; 2) nociceptive pain; 3) neuropathic pain. A graphical depiction of the protocol is shown in Figure 1. At the end of the study, a structured interview was conducted, and researchers annotated patients' comments in order to evaluate the acceptability of such an approach.

Reference measurements

The reference measurements, which will be taken for each participant, will be included in the following Case Report Form (CRF):

1. **a recruitment CRF,** which will contain the demographic information, the Expanded Disability Scale [31] information about the disease and drugs;
2. **a sleep-wake questionnaire CRF,** which the PI will administer to set reminders for each participant to fill in the monitoring questionnaire CRF.

3. **a stratification questionnaire CRF** will allow the classification of patients into the three previously mentioned categories (absence of pain, nociceptive pain, or neuropathic pain) following the procedure described in Figure 2. In particular, this CRF will include the following tools: a) two screening questions (Pain Screen$_1$ and Pain Screen$_2$) to respectively assess the presence of current pain or in the past four weeks; b) the *painDETECT* questionnaire [10]; c) the *Doleur Neuropathique 4 Questions* (DN4) [32]; d) the *Euro Quality of Life 5-dimension 3-level* (EQ-5D-3L) [12] to evaluate the health-related quality of life.

4. **a monitoring questionnaire CRF,** which each participant will fill in through the smartphone$_{participant}$ during the 48h-monitoring, including information about any experienced pain.

5. **a monitoring-treatment questionnaire CRF** will be administered by the PI (or his delegate) through the smartphone$_{project}$ to each participant during the motor neurorehabilitation treatment. It is a reduced version of the Monitoring questionnaire CRF.

Measures' psychometric properties

The EDSS is a method of quantifying disability in MS and monitoring changes in the level of disability over time. It is widely used in clinical trials and in the assessment of people with MS, for whom it resulted to be a valid tool to detect the effectiveness of clinical interventions and to monitor disease progression [33].

The PD-Q has already been used as a diagnostic tool for pain assessment in persons with MS, although not in an Italian population [34]. However, PD-Q was cross-culturally adapted and validated in a mixed population of 100 Italian patients affected by nociceptive or neuropathic pain [35]. The authors showed that PD-Q had an high internal consistency (Cronbach's alpha of 0.89) and a high test-retest reliability (Intraclass Correlation Coefficient of 0.96), suggesting good psychometric and discriminant capabilities for the two types of pain.

The DN4 was translated in Italian and validated as a diagnostic tool for neuropathic pain in a cohort of 158 patients with diabetic neuropathy [36]. In particular, the tool correlated (rho= 0.58) with the short form McGill Pain Questionnaire (a generic tool for pain assessment) and showed a high diagnostic accuracy for painful diabetic neuropathy (areas under the ROC of 0.94). Furthermore, DN4 has been used to characterize neuropathic pain in a cohort of 1249 persons with MS in Italy [37].

The Numerical Pain Rating Scale (NPRS), present in the Monitoring questionnaire CRF, is an unidimensional measure of pain intensity in adults. By using the NPRS, the participant is asked to rate his or her pain on a 0-10 numeric scale, with 0 representing "no pain" and 10 representing "worst possible pain". It has a high test-retest reliability [38], and it is the most common tool used for several pain conditions, including MS [39].

Wearable devices and physiological signals

Each participant will be asked to wear the Empatica E4 wristband, a wearable medical device that records the following physiological signals:

1. **Photoplethysmography (PPG)**, reporting variations in blood volume flow that occur with each heartbeat, affected by both the sympathetic and parasympathetic nervous systems. PPG signal can be exploited to estimate the heart rate, thus allowing the heart rate variability (HRV) analysis and interesting features can be extracted by conducting a more in-depth morphological analysis [40];

2. **Electrodermal activity (EDA)**, representing the activation of the eccrine sweat glands, innervated by the sympathetic nervous system, representing an arousal index Features related to pain sensations can be extracted either from the whole signal or from the two principal components, the tonic (slow changes) and the phasic (fast changes) components [21];

3. **Skin temperature (SKT)**, an index of sympathetic activation, mainly depending on the amount of superficial blood flow;

4. **Three-axis accelerometer data (ACC),** recording physical activity and movement.

Experimental pipeline

The intervention will consist of the seven following phases:

- t_0: The CRF Stratification questionnaire will be administered through a smartphone by the PI (or his delegate). The participant will then be asked to wear the Empatica E4 wristband and be given the

smartphone$_{participant}$, which will be used to fulfill the Monitoring questionnaire CRF. Reminders will be set to fill in the questionnaire based on the Sleep-Wake questionnaire CRF administered in this phase.

- t_0-t_{1a}: The participant will wear the Empatica E4 wristband and complete the Monitoring questionnaire CRF. Reminders will be set hourly during waking hours.
- t_{1a}-t_{1b}: The participant will return to the clinic 24 hours after t_0 and drop off the Empatica E4 and the smartphone$_{participant}$ for data downloading and device recharging. After about an hour, the participant will be asked again to wear the Empatica E4. Then, the Stratification questionnaire CRF will be administered, and the motor neurorehabilitation treatment will commence.
- t_{1b}-t_2: The participant will undergo the motor neurorehabilitation treatment, and every 10 minutes, the PI (or his delegate) will administer the Monitoring-treatment questionnaire CRF through the smartphone$_{project}$.
- t_2: The Stratification questionnaire CRF will be administered, and the participant will receive back the smartphone$_{participant}$.
- t_2-t_3: The participant will wear the Empatica E4 wristband and complete the Monitoring questionnaire CRF. Reminders will be set again hourly during waking hours.
- t_3: Finally, the participant will return to the clinic 24 hours after t_2 and drop off the Empatica E4 and the smartphone$_{participant}$.

For the purpose of this study, each participant accesses to the clinic for three consecutive days: the first and last days are devoted to the study onset and the devices return respectively, while the second one is devoted to the neurorehabilitation treatment. Each session lasts one hours and consists of specific active and passive exercises, based on stimulation for balance control, exercises for the dual motor/cognitive task, training for free walking or assisted with aids and/or ortheses, a defatigue phase with mobilisations and muscle stretching exercises, respiratory awareness. The sequence of exercises is the same for each participant, with some peculiarities relying on the specific individual goals. Robotic or supportive equipment won't be used in these sessions.

Signal and data analysis

Physiological signals recorded through the Empatica E4 wristband will be analyzed in four successive phases: 1) Preprocessing (artifact mitigation, filtering); 2) Segmentation (time-windows detection of physiological signals linked to the assessments); 3) Signal processing and feature extraction; 4) Feature selection. Following this pipeline, we will implement AI algorithms to develop the classifiers and regressors methods indicated in Box 2. Classifiers and regressors will be trained and tested based on the outcomes from the Stratification questionnaire CRF, Monitoring questionnaire CRF, and Monitoring-treatment questionnaire CRF. Validation will be conducted by testing the Leave-One-Subject-Out cross-validation and 10-fold cross-validation. We will also consider adding covariates, either from the Monitoring questionnaire CRF or personal data (e.g., age, information about the pathology, and use of drugs). This will allow verifying, both on a quantitative and qualitative basis, whether there are differences in physiological parameters related to these specific covariates.

The performance of the classifiers will be assessed using the following indicators: accuracy, sensitivity, specificity, and area under the Receiving Operating Characteristic (ROC) curve (or precision and recall when a multi-class classification is applied). Instead, the regression models' performance will be assessed using the following indicators: root mean squared error, absolute error, relative error, and correlation.

Box 2. Classifiers and regressors methods for pain assessment

Pain class	Absence vs Presence of pain
	Nociceptive vs Neuropathic pain
	Absence of pain vs Nociceptive pain vs Neuropathic pain
Pain intensity	Multi-class classifier, based on literature guidelines
	Regression model

Objectives and related endpoints

1. **Feasibility of developing a differential diagnosis method based on physiological signals recorded using wearable sensors to assess the absence or presence of pain.** The related primary endpoint will be evaluated based on the number of available instances to be processed for determining the absence/presence of pain, which means the number of concurrent physiological signals registrations and pain assessments. If this endpoint is met, a predictive test will be developed based on AI techniques and physiological parameters. The diagnostic performance of this test will be evaluated against the state-of-the-art methods (questionnaires) by evaluating standard performance indicators (i.e., sensitivity, specificity, predictive values). The endpoint will be considered achieved if at least 80% of the instances are available. The diagnostic accuracy will be calculated using the CRF Stratification and CRF Monitoring questionnaires as a reference. The threshold for the diagnostic accuracy to define the endpoint achieved is set at 75%.

2. **Feasibility of developing a regression model based on physiological signals recorded using wearable sensors to assess pain intensity (secondary endpoint).** The related secondary endpoint will be evaluated based on the number of available instances to be processed to assess pain intensity, i.e., the number of concurrent physiological signals registrations and pain assessments. If this endpoint is met, a regression model will be developed based on AI techniques and physiological parameters. The diagnostic performance of this test will be evaluated against the state-of-the-art methods (questionnaires) by evaluating standard performance indicators (i.e., accuracy, mean squared error). The endpoint will be achieved if at least 80% of the instances are available. The coefficient of determination of the regression model will be calculated using the CRF Stratification questionnaire and CRF Monitoring questionnaire as a reference. The threshold for the coefficient of determination to define the endpoint achieved is set at 0.5.

3. **Feasibility of developing a differential diagnosis method based on physiological signals recorded using wearable sensors to discern between nociceptive and neuropathic pain (secondary endpoint).** The related secondary endpoint will be assessed based on the number of available instances to be processed to distinguish between nociceptive and neuropathic pain, i.e., the number of concurrent physiological signals registrations and pain assessments. If this endpoint is met, a predictive test will be developed based on AI techniques and physiological parameters. The diagnostic performance of this test will be evaluated against the state-of-the-art methods (questionnaires) by evaluating standard performance indicators (i.e., sensitivity, specificity, predictive values). The endpoint will be considered achieved if at least 80% of the instances are available. The diagnostic accuracy will be calculated using the CRF Stratification and CRF Monitoring questionnaires as a reference. The threshold to define the endpoint achieved is set at 75%.

Sample size

Given the study's exploratory nature, the effect size is unknown; thus, it is not possible to calculate the sample size accurately. However, the decision to include at least 15 participants is in line with the previous literature on pilot and feasibility study design, based on practical considerations [41] as well as the specific aims of this study [42].

Patient and public involvement

Research questions and outcome measures were identified based on the research team's experience and patients' priorities. Having a tool that continuously and automatically monitors pain would help patients in better control and personalize their antalgic therapy, in turn improving their quality of life. Patients will be first involved in the study at the recruitment phase. After the three days monitoring, participants will be asked to describe their experience, the pros and cons of the approach used in the study, and any advice on how to improve the acceptability. At the end of the whole study, participants will be informed of the results. Together with patient advisers, patients involved in the study will be acknowledged in future scientific publications and presentations.

Status of the study

The study is currently in progress. Recruitment began in January 2023 and this phase is expected to be completed in October 2023. Preliminary analyses have already been conducted, although the exhaustive evaluation of the endpoints will be conducted after the data collection phase is completed.

Ethics and dissemination

The study will be conducted according to the ethical principles established in the Declaration of Helsinki and has been subjected to approval by the local Ethical Committee (285-2022-SPER-AUSLBO). Any changes to the protocol will be proposed to the local Ethical Committee as a request for amendment. Although it is not foreseen that there will be a direct short-term benefit to participants, the research protocol presents minimal risks for the participants and no burden, as required by Article 28 of the Declaration of Helsinki.

Personal data will be retained in agreement with the GDPR guidance for ten years. Specifically, the PI and co-PIs will be responsible for archiving and preserving the essential study documents before, during, and after the completion of the study, according to the timeframe required by the current regulations and good clinical practice.

Researchers involved in the study will disseminate the results in a timely and complete manner, participating in conferences and writing scientific articles for submission to international journals. In addition, the findings from the study will form part of a doctoral dissertation for one of the authors (SM). The researchers will scrupulously, objectively, and impartially provide as much evidence and information as possible on aspects such as the state-of-the-art literature before the study, the original purpose, and methods defined before conducting the research, any changes in objectives and methods since the study were commenced, the significant results achieved, including negative or null results and, finally, the possible interpretations, applicability, and limitations of the findings.

Discussion

In regular clinical practice, pain assessment is usually carried out by administering subjective scales and questionnaires. Although their usefulness for the subjective quantification of pain, these tools can lead to inaccurate assessments due to the influence of many factors, such as emotional and cognitive factors [15]. In addition, they cannot be administered to those patients unable to communicate verbally. Therefore, identifying optimal physiological parameters recorded through wearable devices and using artificial intelligence algorithms would allow the development of automatic methods capable of determining the absence or presence of pain in MS patients, its intensity, and distinguishing pain as nociceptive or neuropathic.

Such continuous and objective pain monitoring in everyday life activities and during treatments would overcome the limitations imposed by the tools currently used in clinical practice [13]. In particular, continuous and objective monitoring would bring about several advantages. First, this pain assessment disregards the patients' ability or willingness to communicate their pain verbally. Second, this approach is supposed to provide a completely automatic method that would not require spending time ad hoc to administer scales and questionnaires, as it could be used in hospital or daily life contexts while patients are involved in other activities. Lastly, having a more reliable method to discriminate between nociceptive and neuropathic pain would allow a better personalization of the antalgic therapy.

The long-term goal is to integrate such an innovative method into regular clinical practice as a tool for clinical decision-making for the antalgic therapy to be chosen. Implementing this method would allow PwMS to be monitored both during neurorehabilitation treatment and in a pervasive context. This would allow for a timelier assessment of the patient's pain, ultimately aiming to ameliorate their quality of life. Prospectively, if properly calibrated, such a method could allow quantification and monitoring of pain in patients unable to express it verbally, such as patients with severe brain injury, in a minimally conscious state, or with aphasia.

An innovative aspect of this study relies on the possibility of overcoming the "etiological" boundaries of pain at the measurement level. This would be extremely useful, considering that, in many pathologies, different types of pain may coexist. For example, in brain injury, there may be a mix of nociceptive and neuropathic pain, both of central and peripheral origin. This study could bring initial insights into how pain can be measured by recording a minimum set of physiological parameters based on physiological indicators invariant to the pathology [24]. In other words, we will be able to assess whether the parameters to be measured are independent of the underlying pathology, precisely as is the case for different physiological parameters such as body temperature or heart rate. For the latter, differences of quantitative nature (e.g., fever) give rise to specific diagnostic profiles only in combination with other data (e.g., body temperature changes and other diagnostic indicators), being the measurement of the temperature parameter independent of the pathology that modifies it. Similarly, from the combination of physiological parameters of pain, diagnostic combinations ("profiles") could be identified for specific pathologies.

The proposed study is also relevant for health systems because it aims to improve the pain assessment phase, which is necessary to choose the most appropriate antalgic therapy for the patient [43]. In addition, such a system would allow the prescription of more personalized pain treatment plans, make efficient use of resources, and minimize the waste resulting from the incorrect choice of ineffective strategies to improve the patient's pain status [44]. In addition, the proposed protocol is also relevant in terms of research, as the availability of an objective system of pain quantification, together with the already available subjective assessment tools, would make the quantification of treatment effects in the context of RCTs and other studies undoubtedly more accurate and less prone to interpretive bias.

The methodology presented here may suffer from several limitations. First, being designed as an exploratory feasibility study, the limited sample size may hinder the development of robust and reliable methods for objectively assessing pain and, consequently, achieving reliable results and good performance. Furthermore, additional specific personal, contextual, or health-related factors (e.g., age, sex, physical activity level, type of disability) can significantly impact the physiological parameters used to develop automatic pain assessment methods [45]. Thus, our models may not be robust enough to properly assess pain should these factors not be adequately controlled.

In conclusion, in this paper we presented a protocol to evaluate the feasibility of developing automatic methods for pain assessment in Persons with Multiple Sclerosis based on physiological signals and AI algorithms. In addition, we illustrated the intervention by highlighting the state-of-the-art and innovative tools to obtain reliable and robust methods for automatic pain assessment. Such an approach, if proven feasible, can lead to significant progress in the field of pain management by providing a better characterization of pain and, therefore, more timely and efficient interventions to control it.

Contributors

SM: Conceptualization, Methodology, Data processing, Formal analysis, Manuscript – initial draft preparation, review, and editing. SO: Conceptualization, Methodology, Data processing, Formal analysis, Manuscript – initial draft preparation, review, and editing. FDG: Methodology, Manuscript – review and editing. GL: Conceptualization, Manuscript – review and editing. SP: Site facilitator, Manuscript – review and editing. LS: Site facilitator, Methodology, Manuscript – review and editing. LC: Conceptualization, Methodology, Funding acquisition, Manuscript – review, and editing. FLP: Conceptualization, Methodology, Formal analysis, Manuscript – initial draft preparation, review, and editing.

Funding

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1   Raja SN, Carr DB, Cohen M, *et al.* The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain* 2020;**161**:1976–82. doi:10.1097/j.pain.0000000000001939

2   Clarke C, Howard R, Rossor M, *et al. Neurology: A Queen Square textbook: Second edition*. 2016. doi:10.1002/9781118486160

3   Seixas D, Foley P, Palace J, *et al.* Pain in multiple sclerosis: A systematic review of neuroimaging studies. *NeuroImage Clin* 2014;**5**:322–31. doi:10.1016/j.nicl.2014.06.014

4   Sullivan AB, Scheman J, LoPresti A, *et al.* Interdisciplinary Treatment of Patients with Multiple Sclerosis and Chronic Pain. *Int J MS Care* 2012;**14**:216–20. doi:10.7224/1537-2073-14.4.216

5   O'Sullivan SB, Schmitz TJ, Fulk GD. *Physical Rehabilitation*. 2014.

6   Marck CH, De Livera AM, Weiland TJ, *et al.* Pain in People with Multiple Sclerosis: Associations with Modifiable Lifestyle Factors, Fatigue, Depression, Anxiety, and Mental Health Quality of Life. *Front Neurol* 2017;**8**. doi:10.3389/fneur.2017.00461

7   Benrud-Larson LM, Wegener ST. Chronic pain in neurorehabilitation populations: Prevalence, severity and impact. *NeuroRehabilitation* 2000;**14**:127–37. doi:10.3233/NRE-2000-14302

8   Widerstrom-Noga E. The assessment and treatment of pain syndromes in neurorehabilitation. In: *Oxford Textbook of Neurorehabilitation*. 2015. 314–27.

9   Haefeli M, Elfering A. Pain assessment. *Eur Spine J* 2006;**15**:S17–24. doi:10.1007/s00586-005-1044-x

10 Freynhagen R, Baron R, Gockel U, *et al.* pain DETECT : a new screening questionnaire to identify neuropathic components in patients with back pain. *Curr Med Res Opin* 2006;**22**:1911–20. doi:10.1185/030079906X132488

11 Bouhassira D, Attal N, Alchaar H, *et al.* Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). *Pain* 2005;**114**:29–36. doi:10.1016/j.pain.2004.12.010

12 Mozzi A, Meregaglia M, Lazzaro C, *et al.* A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. *Clin Outcomes Res* 2016;:267. doi:10.2147/CEOR.S98226

13 Werner P, Lopez-Martinez D, Walter S, *et al.* Automatic Recognition Methods Supporting Pain Assessment: A Survey. *IEEE Trans Affect Comput* 2019;**X**:1–1. doi:10.1109/TAFFC.2019.2946774

14 Morton DL, Jones AKP. Brain imaging of pain : state of the art. 2016;:613–24.

15 Subramaniam SD, Doss B, Chanderasekar LD, *et al.* Scope of physiological and behavioural pain assessment techniques in children – A review. *Healthc Technol Lett* 2018;**5**:124–9. doi:10.1049/htl.2017.0108

16 Gilron I, Baron R, Jensen T. Neuropathic Pain: Principles of Diagnosis and Treatment. *MAYO Clin Proc* 2015;**90**:532–45. doi:10.1016/j.mayocp.2015.01.018

17   Dou Z, Yang L. The Application of Functional Magnetic Resonance Imaging in Neuropathic Pain. In: *Medical Imaging - Principles and Applications [Working Title]*. IntechOpen 2019. doi:10.5772/intechopen.89200

18   Teixeira M, Mancini C, Wicht CA, *et al.* Beta Electroencephalographic Oscillation Is a Potential GABAergic Biomarker of Chronic Peripheral Neuropathic Pain. *Front Neurosci* 2021;**15**. doi:10.3389/fnins.2021.594536

19   Hohenschurz-Schmidt DJ, Calcagnini G, Dipasquale O, *et al.* Linking Pain Sensation to the Autonomic Nervous System: The Role of the Anterior Cingulate and Periaqueductal Gray Resting-State Networks. *Front Neurosci* 2020;**14**. doi:10.3389/fnins.2020.00147

20   Cortelli P, Giannini G, Favoni V, *et al.* Nociception and autonomic nervous system. *Neurol Sci* 2013;**34**. doi:10.1007/s10072-013-1391-z

21   Boucsein W. *Electrodermal Activity*. Boston, MA: : Springer US 2012. doi:10.1007/978-1-4614-1126-0

22   Hui TKL, Sherratt RS. Coverage of Emotion Recognition for Common Wearable Biosensors. *Biosensors* 2018;**8**:30. doi:10.3390/bios8020030

23   Li F, Yang L, Shi H, *et al.* Differences in photoplethysmography morphological features and feature time series between two opposite emotions: Happiness and sadness. *Artery Res* 2017;**18**:7. doi:10.1016/j.artres.2017.02.003

24   Naranjo-Hernandez D, Reina-Tosina J, Roa LM. Sensor Technologies to Manage the Physiological Traits of Chronic Pain: A Review. *Sensors (Basel)* 2020;**20**. doi:10.3390/s20020365

25   Johnson A, Yang F, Gollarahalli S, *et al.* Use of Mobile Health Apps and Wearable Technology to Assess Changes and Predict Pain During Treatment of Acute Pain in Sickle Cell Disease: Feasibility Study. *JMIR mHealth uHealth* 2019;**7**:e13671. doi:10.2196/13671

26   Badura A, Masłowska A, Myśliwiec A, *et al.* Multimodal Signal Analysis for Pain Recognition in Physiotherapy Using Wavelet Scattering Transform. *Sensors* 2021;**21**:1311. doi:10.3390/s21041311

27   Moscato S, Orlandi S, Giannelli A, *et al.* Automatic pain assessment on cancer patients using physiological signals recorded in real-world contexts. In: *2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)*. IEEE 2022. 1931–4. doi:10.1109/EMBC48229.2022.9871990

28   Leroux A, Rzasa-Lynn R, Crainiceanu C, *et al.* Wearable Devices: Current Status and Opportunities in Pain Assessment and Management. *Digit Biomarkers* 2021;**5**:89–102. doi:10.1159/000515576

29   Chen J, Abbod M, Shieh J-S. Pain and Stress Detection Using Wearable Sensors and Devices—A Review. *Sensors* 2021;**21**:1030. doi:10.3390/s21041030

30   EMPATICA I. Empatica Sensors Empatica E4 TechSpecs. 2015;:4–8.www.empatica.com/docs (accessed 31 Jan 2019).

31   Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). *Neurology* 1983;**33**:1444–1444. doi:10.1212/WNL.33.11.1444

32   Pfizer. Pharmacy focus on pain - DN4 Questionnaire. 2016. https://www.pfizerpro.ie/sites/default/files/dn.pdf

33   Meyer-Moock S, Feng Y-S, Maeurer M, *et al.* Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. *BMC Neurol* 2014;**14**:58. doi:10.1186/1471-2377-14-58

34   Kratz AL, Whibley D, Alschuler KN, *et al.* Characterizing chronic pain phenotypes in multiple sclerosis: a nationwide survey study. *Pain* 2021;**162**:1426–33. doi:10.1097/j.pain.0000000000002136

35   Migliore A, Gigliucci G, Moretti A, *et al.* Cross Cultural Adaptation and Validation of Italian Version

of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain. *Pain Res Manag* 2021;**2021**:1–7. doi:10.1155/2021/6623651

36   Spallone V, Morganti R, D'Amato C, *et al.* Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. *Diabet Med* 2012;**29**:578–85. doi:10.1111/j.1464-5491.2011.03500.x

37   Solaro C, Cella M, Signori A, *et al.* Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. *J Neurol* 2018;**265**:828–35. doi:10.1007/s00415-018-8758-2

38   Hawker GA, Mian S, Kendzerska T, *et al.* Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF. *Arthritis Care Res (Hoboken)* 2011;**63**:S240–52. doi:10.1002/acr.20543

39   Rivel M, Achiron A, Dolev M, *et al.* Unique features of central neuropathic pain in multiple sclerosis: Results of a cluster analysis. *Eur J Pain* 2022;**26**:1107–22. doi:10.1002/ejp.1934

40   Elgendi M. On the Analysis of Fingertip Photoplethysmogram Signals. *Curr Cardiol Rev* 2012;**8**:14–25. doi:10.2174/157340312801215782

41   Teresi JA, Yu X, Stewart AL, *et al.* Guidelines for Designing and Evaluating Feasibility Pilot Studies. *Med Care* 2022;**60**:95–103. doi:10.1097/MLR.0000000000001664

42   Moore CG, Carter RE, Nietert PJ, *et al.* Recommendations for Planning Pilot Studies in Clinical and Translational Research. *Clin Transl Sci* 2011;**4**:332–7. doi:10.1111/j.1752-8062.2011.00347.x

43   Gordon DB, Dahl JL, Miaskowski C, *et al.* American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society quality of care task force. *Arch Intern Med* 2005;**165**:1574–80. doi:10.1001/archinte.165.14.1574

44   Sinatra R. Causes and Consequences of Inadequate Management of Acute Pain. *Pain Med* 2010;**11**:1859–71. doi:10.1111/j.1526-4637.2010.00983.x

45   Moscato S, Lo Giudice S, Massaro G, *et al.* Wrist Photoplethysmography Signal Quality Assessment for Reliable Heart Rate Estimate and Morphological Analysis. *Sensors* 2022;**22**:5831. doi:10.3390/s22155831

Figure titles

Figure 1. PAINLESS study protocol

**Figure 2.** Stratification algorithm

Study flowchart

168x98mm (220 x 220 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

```
                                    ┌─────────┐
                                    │  START  │
                                    └────┬────┘
                              ┌──────────┴──────────┐
                              │ PainScreen₂         │
                              │ PainScreen₂         │
                              │ painDETECT_mod      │
                              │ DN4                 │
                              └──────────┬──────────┘
            ┌──────────────────────────┼──────────────────────────┐
   ┌────────┴────────┐                                    ┌────────┴────────┐
   │ Total score     │                                    │ Total score     │
   │ painDETECT_mod  │                                    │ DN4             │
   └────────┬────────┘                                    └────────┬────────┘
   ┌────────┴────────┐                                    ┌────────┴────────┐
   │  Summary        │                                    │ Summary score_DN4│
   │  score_painDETECTmod│                                └────────┬────────┘
   └────────┬────────┘
```

0 Absence of pain	**1** Nociceptive pain	**2** Unclear	**3** Neuropathic pain		**0** Absence of pain	**1** Nociceptive pain	**2** Neuropathic pain

$$\text{Summary score}_{painDETECTmod} + \text{Summary score}_{DN4} = \text{Summary Score}_{Pain}$$

0 Absence of pain	**1-2** Possible Nociceptive pain	**3-5** Possible Neuropathic pain

Stratification algorithm

164x144mm (150 x 150 DPI)

Titolo dello studio	Valutazione del dolore mediante sensori indossabili in Neuroriabilitazione
Acronimo dello studio	PAINLESS (**PAI**n in **N**eurorehabilitation with wearab**LES**ensor**S**)
Codice del protocollo	001.2022.ISNB.NeuroRehab.MR-NR
Struttura	UO di Medicina Riabilitativa e Neuroriabilitazione (SC)
PI	Fabio La Porta
Promotore	IRCCS Istituto delle Scienze Neurologiche di Bologna
Finanziatore	-

Modulo di consenso informato

Il/La sottoscritto/a_____

nato/a a_____ il_____

e residente a_____ in Via_____

telefono_____

in qualità di diretto Interessato

<u>dichiaro</u>

- di aver ricevuto esaurienti spiegazioni in merito alla richiesta di partecipazione allo studio, in particolare sulle finalità e sulle procedure;

- di aver avuto la possibilità di porre domande e di aver ricevuto risposte soddisfacenti;

- di aver letto e compreso il foglio informativo che mi è stato consegnato con sufficiente anticipo;

- di aver compreso che la partecipazione è volontaria, e che potrò ritirarmi dallo studio in qualsiasi momento, senza dover dare spiegazioni e senza che ciò influenzi in alcun modo la mia futura assistenza;

- di essere consapevole che, se ritirerò il mio consenso, i dati raccolti prima del ritiro del consenso saranno utilizzati dal ricercatore;

Conseguentemente a queste dichiarazioni:

□ **accetto** di partecipare allo studio PAINLESS	□ **rifiuto** di partecipare allo studio PAINLESS

Nome e Cognome…………………………………………………………………………..

Data…………………………….. Firma…………………………………………………………………………

Nome della persona che raccoglie il consenso……………………………………………………

Data…………………………….. Firma…………………………………………………………………………

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find

each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to

include the missing information. If you are certain that an item does not apply, please write "n/a" and

provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRITreporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A,

Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and

Elaboration: Guidance for protocols of clinical trials. BMJ. 2013;346:e7586

Reporting Item			Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1

Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	n/a
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	8
Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	n/a
Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	8
Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and	n/a

other individuals or groups overseeing the trial, if

applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	2-4
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	2-3
Objectives	#7	Specific objectives or hypotheses	4
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4

Methods: Participants, interventions, and outcomes

| Study setting | #9 | Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained | 4 |

Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	Box 1
Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	4-5
Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	n/a
Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	n/a
Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	n/a
Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	6

Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	Figure 1
Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	6
Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	n/a
Methods: Assignment of interventions (for controlled trials)			
Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	n/a
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque,	n/a

sealed envelopes), describing any steps to conceal the

sequence until interventions are assigned

Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	n/a
Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	n/a
Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	n/a

Methods: Data collection, management, and analysis

Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	5

Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	n/a
Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	n/a
Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	5-6
Statistics: additional analyses	#20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	n/a
Statistics: analysis population and missing data	#20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	n/a
Methods: Monitoring			
Data monitoring: formal committee	#21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further	n/a

details about its charter can be found, if not in the
protocol. Alternatively, an explanation of why a DMC is
not needed

Data monitoring: interim analysis	#21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	n/a
Harms	#22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	n/a
Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	n/a

Ethics and dissemination

Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	7
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	7

Consent or assent	[#26a](#26a)	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	7
Consent or assent: ancillary studies	[#26b](#26b)	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	7
Confidentiality	[#27](#27)	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	7
Declaration of interests	[#28](#28)	Financial and other competing interests for principal investigators for the overall trial and each study site	n/a
Data access	[#29](#29)	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	n/a
Ancillary and post trial care	[#30](#30)	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
Dissemination policy: trial results	[#31a](#31a)	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	7

| Dissemination policy: authorship | #31b | Authorship eligibility guidelines and any intended use of professional writers | n/a |
| Dissemination policy: reproducible research | #31c | Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code | n/a |

Appendices

| Informed consent materials | #32 | Model consent form and other related documentation given to participants and authorised surrogates | n/a |
| Biological specimens | #33 | Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable | n/a |

The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist was completed on 06. March 2023 using https://www.goodreports.org/, a tool made by the EQUATOR Network in collaboration with Penelope.ai